Circulating Fibroblast Growth Factor-23 Is Associated With Fat Mass and Dyslipidemia in Two Independent Cohorts of Elderly Individuals
- 1 January 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 31 (1), 219-227
- https://doi.org/10.1161/atvbaha.110.214619
Abstract
Objective—: Disturbances in mineral metabolism define an increased cardiovascular risk in patients with chronic kidney disease. Fibroblast growth factor-23 (FGF23) is a circulating regulator of phosphate and vitamin D metabolism and has recently been implicated as a putative pathogenic factor in cardiovascular disease. Because other members of the FGF family play a role in lipid and glucose metabolism, we hypothesized that FGF23 would associate with metabolic factors that predispose to an increased cardiovascular risk. The goal of this study was to investigate the relationship between FGF23 and metabolic cardiovascular risk factors in the community. Methods and Results—: Relationships between serum FGF23 and body mass index (BMI), waist circumference, waist-to-hip ratio, serum lipids, and fat mass were examined in 2 community-based, cross-sectional cohorts of elderly whites (Osteoporotic Fractures in Men Study: 964 men aged 75±3.2; Prospective Investigation of the Vasculature in Uppsala Seniors study: 946 men and women aged 70). In both cohorts, FGF23 associated negatively with high-density lipoprotein and apolipoprotein A1 (7% to 21% decrease per 1-SD increase in log FGF23; P P P P P <0.05). Conclusion—: We report for the first time on associations between circulating FGF23, fat mass, and adverse lipid metabolism resembling the metabolic syndrome, potentially representing a novel pathway(s) linking high FGF23 to an increased cardiovascular risk.Keywords
This publication has 56 references indexed in Scilit:
- Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly populationAtherosclerosis, 2009
- Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the communityAtherosclerosis, 2009
- High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patientsNephrology Dialysis Transplantation, 2009
- Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney diseaseNephrology Dialysis Transplantation, 2008
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisThe New England Journal of Medicine, 2008
- Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21Journal of Biological Chemistry, 2007
- Endocrine Regulation of Energy Metabolism by the SkeletonCell, 2007
- βKlotho is required for metabolic activity of fibroblast growth factor 21Proceedings of the National Academy of Sciences of the United States of America, 2007
- Evaluation of Gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in mL/min/1.73 m2from the cystatin C values in mg/LScandinavian Journal of Clinical and Laboratory Investigation, 2007
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006